Cannabichromene (CBC) New Applications CAS 20675-51-8​​

Cannabichromene (CBC)  New Applications

​​1. Breakthrough in Antidepressant Research​​

A 2025 study published in Naunyn-Schmiedeberg’s Archives of Pharmacologydemonstrated CBC’s antidepressant effects in mice models of chronic stress. CBC bound strongly to cannabinoid receptor 2 (CB2) with higher affinity than CBD or THC, reducing immobility (a depressive behavior marker) by 40% at 20 mg/kg doses. It also lowered stress-induced corticosterone and nitrite levels, suggesting potential for human therapeutic use .

​​2. Anti-Cancer Potential in Pancreatic and Glioblastoma Models​​

​​Pancreatic Cancer​​: CBC induced apoptosis and ferroptosis in pancreatic cancer cells by upregulating ferroptosis-related genes (e.g., HMOX1) and activating TRPV1/CB2 receptors. In vivo xenograft models showed significant tumor growth inhibition .

Glioblastoma​​: CBC exhibited strong binding affinity to glioblastoma-associated targets GPR55 and PINK1. Combined with CBD and CBG, it reduced glioblastoma cell viability by 60% in U87MG and T98G cell lines .

​​3. Synergistic Pain Relief via TRPA1 Modulation​​

A 2025 review highlighted CBC’s role in pain management through TRPA1 receptor interaction. Preclinical studies showed CBC reduced edema and hyperalgesia by 35% in animal models, comparable to gabapentin. Its synergy with THC and CBD was noted as a promising "entourage effect" for chronic pain .

​​4. Advancements in Bioproduction​​

​​Synthetic Biology​​: Researchers at Dalian University of Technology engineered Saccharomyces cerevisiaeto produce cannabichromenic acid (CBCA, CBC’s precursor) at 31.7 μg/L, a 25.8× improvement over natural cannabis. This method reduced production time from 120 days to 100 hours .

​​Chirality Control​​: A 2025 study introduced a chiral NMR method to distinguish (R)- and (S)-CBC enantiomers, critical for optimizing bioactivity in drug development .

​​5. Cosmetic and Dermatological Applications​​

CBC’s anti-inflammatory properties made headlines in skincare. A 2025 clinical trial found CBC-based formulations reduced acne severity by 50% in 8 weeks by suppressing sebaceous gland activity and fatty acid production .

​​6. Challenges and Future Directions​​

​​Clinical Validation​​: Most studies remain preclinical; human trials are needed to confirm safety and efficacy.

​​Standardization​​: Variability in CBC enantiomer ratios across cannabis strains complicates research reproducibility